ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

DCT Board Okays Kaposi Study, Blocks Monitoring Plan

February 26, 1982

NCI Proposes Inviting Academic Labs To Submit New Therapies For Development

January 23, 1998

Studies of Oncotype DX Test Presented at ASCO Symposium

January 31, 2014

President Clinton Seeks 8% Increase For NCI; Most Institute Take Cuts In $10 Bll. NIH Budget

April 16, 1993

NIH To Sponsor Animal Care, Human Protection Workshop

February 21, 1986

Conversation With The Cancer Letter: Ronald DePinho Says Moon Shots Will Go On

January 18, 2013